title: Flumazenil use in an emergency department: a survey.
abstract: OBJECTIVE
  To evaluate the efficacy of flumazenil use by a one-year survey of practice in tan emergency department.
  
  
  METHODS
  During a one-year period, an observational prospective study in the emergency department of an urban community hospital enrolled every patient admitted with a history of pure or mixed benzodiazepine acute poisoning. Case records were secondarily reviewed by an expert group. Actual flumazenil use during hospitalization was compared to currently recommended indications. In order to evaluate the efficacy of flumazenil use, patients who received flumazenil were matched with those who did not and effects on mortality, morbidity, number of costly procedures (CT scan, diagnostic toxicology, etc.) and duration of hospital stay were determined.
  
  
  RESULTS
  Of the 1529 patients admitted in 1 year for acute poisoning, 478 reportedly ingested at least one benzodiazepine. Twenty-nine patients (6%) received flumazenil in the emergency department whereas the expert reviewers recommended flumazenil use in only 18 (3.7%). In 11/29 (38%) cases, the use of fumazenil was considered inappropriate. The expert group considered flumazenil to be contraindicated in 93 of 478 patients. Nonetheless, flumazenil was used in 11 patients (rate of potentially harmful flumazenil use: 11/93; 12%), and a severe complication occurred in one of these patients after flumazenil. No significant difference could be shown in outcome, complication rate, number of complex procedures or duration of hospital stay between patients who received flumazenil and matched patients who did not.
  
  
  CONCLUSIONS
  The use of flumazenil in the clinical practice of an emergency department fails to show any beneficial effect in adult patients. Moreover, contraindications are frequently overlooked and this may expose patients to substantial risk of complications.
authors.affiliation: Northern France Poison Center, Regional University Hospital, Lille, France. mmathieu@chru-lille.fr
authors.forename: M
authors.initials: M
authors.lastname: Mathieu-Nolf
authors.forename: M A
authors.initials: MA
authors.lastname: Babé
authors.forename: V
authors.initials: V
authors.lastname: Coquelle-Couplet
authors.forename: C
authors.initials: C
authors.lastname: Billaut
authors.forename: P
authors.initials: P
authors.lastname: Nisse
authors.forename: D
authors.initials: D
authors.lastname: Mathieu
mesh_terms: D000293:Adolescent; D000328:Adult; D014151:Anti-Anxiety Agents / Q000506:poisoning*; D000931:Antidotes / Q000009:adverse effects / Q000627:therapeutic use*; D000075202:Contraindications; D004636:Emergency Service, Hospital; D005260:Female; D005442:Flumazenil / Q000009:adverse effects / Q000627:therapeutic use*; D006786:Hospitals, Urban; D006801:Humans; D008297:Male; D011446:Prospective Studies; D013406:Suicide, Attempted
chemical_list: D014151:Anti-Anxiety Agents; D000931:Antidotes; D005442:Flumazenil